PureTech Health (GB:PRTC) has released an update.
PureTech Health plc, a clinical-stage biotherapeutics company, has disclosed its total voting rights and issued share capital at the end of May 2024, highlighting 270,814,102 voting rights and an issued share capital of 289,468,159 Ordinary Shares, with 18,654,057 shares held in treasury. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules. PureTech Health is advancing a substantial pipeline of 29 therapeutics, including two with FDA and European approval and one pending FDA approval, through its extensive network and R&D efforts.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
